(Vienna, 02 July 2021) After identifying some exciting new potential treatments uses for T20K, Cyxone AB announced that the company has entered into a research collaboration with Christian Gruber, the inventor of T20K and Gernot Schabbauer from the Medical University of Vienna. The aim of the study is to deepen the understanding of the mode of action (MoA) of T20K and to explore these new uses and the potential to provide significant additional therapeutic benefit in a model for multiple sclerosis. The study will start later this month, with planned readout in June 2022, and constitutes studies required for approval to test in humans with the new administration form.
T20K is a potential first-in-class peptide drug candidate that shows promise as a novel and safe therapy which can halt the progression of MS. T20K has been shown to both delay disease development and to halt its progression once disease has been initiated in animal models, thereby positioning T20K as a therapy for early intervention in MS which could potentially improve the quality of life for MS patients by delaying or even stopping the diseases progression. The collaboration with MedUni Vienna will explore if there is a therapeutic effect which can be beneficial for other MS patient subsets. The project is part of the ongoing preclinical development activities for T20K and the studies are important to be able to apply for approval to go into clinical phase I.
“I am very pleased that Cyxone has chosen our lab for its studies” said Gernot Schabbauer, “I will work in close collaboration with Christian Gruber, the inventor of T20K, and Cyxone, and I have a keen interest in studying the immune effect and therapeutic effect of this potentially powerful new therapeutic candidate in our novel experimental design.”
The aim is also to confirm the results from previously performed studies with T20K in an in vivo model. A new study design will be applied in this collaboration with the purpose of gaining more in-depth knowledge of the MoA and to deepen the scientific understanding of how T20K works in the body. New possibilities for the treatment will also be tested to determine if there is broader potential for T20K.